NANOBIOTIX (NANO.PA) Stock Fundamental Analysis

EPA:NANO • FR0011341205

21.8 EUR
-0.5 (-2.24%)
Last: Feb 20, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

1

NANO gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 78 industry peers in the Biotechnology industry. Both the profitability and financial health of NANO have multiple concerns. NANO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • NANO had negative earnings in the past year.
  • In the past year NANO has reported a negative cash flow from operations.
  • In the past 5 years NANO always reported negative net income.
  • In the past 5 years NANO always reported negative operating cash flow.
NANO.PA Yearly Net Income VS EBIT VS OCF VS FCFNANO.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • NANO has a Return On Assets of -114.32%. This is in the lower half of the industry: NANO underperforms 78.21% of its industry peers.
Industry RankSector Rank
ROA -114.32%
ROE N/A
ROIC N/A
ROA(3y)-79.59%
ROA(5y)-62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NANO.PA Yearly ROA, ROE, ROICNANO.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K

1.3 Margins

  • NANO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NANO.PA Yearly Profit, Operating, Gross MarginsNANO.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100K -200K -300K -400K -500K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • NANO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • NANO has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for NANO has been increased compared to 5 years ago.
  • NANO has a worse debt/assets ratio than last year.
NANO.PA Yearly Shares OutstandingNANO.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
NANO.PA Yearly Total Debt VS Total AssetsNANO.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • NANO has an Altman-Z score of -11.90. This is a bad value and indicates that NANO is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of NANO (-11.90) is worse than 76.92% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -11.9
ROIC/WACCN/A
WACC7.89%
NANO.PA Yearly LT Debt VS Equity VS FCFNANO.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

  • A Current Ratio of 0.63 indicates that NANO may have some problems paying its short term obligations.
  • With a Current ratio value of 0.63, NANO is not doing good in the industry: 80.77% of the companies in the same industry are doing better.
  • A Quick Ratio of 0.63 indicates that NANO may have some problems paying its short term obligations.
  • NANO's Quick ratio of 0.63 is on the low side compared to the rest of the industry. NANO is outperformed by 75.64% of its industry peers.
Industry RankSector Rank
Current Ratio 0.63
Quick Ratio 0.63
NANO.PA Yearly Current Assets VS Current LiabilitesNANO.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • NANO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -47.30%.
  • The Revenue for NANO has decreased by -138.77% in the past year. This is quite bad
EPS 1Y (TTM)-47.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.09%
Revenue 1Y (TTM)-138.77%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%186.77%

3.2 Future

  • NANO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.40% yearly.
  • The Revenue is expected to grow by 19.60% on average over the next years. This is quite good.
EPS Next Y46.17%
EPS Next 2Y18.23%
EPS Next 3Y22.28%
EPS Next 5Y13.4%
Revenue Next Year24.15%
Revenue Next 2Y74.49%
Revenue Next 3Y23.29%
Revenue Next 5Y19.6%

3.3 Evolution

NANO.PA Yearly Revenue VS EstimatesNANO.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 200M 400M 600M
NANO.PA Yearly EPS VS EstimatesNANO.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NANO. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NANO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NANO.PA Price Earnings VS Forward Price EarningsNANO.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NANO.PA Per share dataNANO.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1

4.3 Compensation for Growth

  • NANO's earnings are expected to grow with 22.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.23%
EPS Next 3Y22.28%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for NANO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NANOBIOTIX

EPA:NANO (2/20/2026, 7:00:00 PM)

21.8

-0.5 (-2.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-24
Earnings (Next)03-31
Inst Owners28.98%
Inst Owner ChangeN/A
Ins Owners0.63%
Ins Owner ChangeN/A
Market Cap1.05B
Revenue(TTM)-14.04M
Net Income(TTM)-51.64M
Analysts85
Price Target23.32 (6.97%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.27%
PT rev (3m)20.25%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-22.09%
EPS NY rev (3m)-20.63%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-19.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.09
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.64
OCFYN/A
SpS-0.29
BVpS-1.42
TBVpS-1.43
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -114.32%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-79.59%
ROA(5y)-62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover-0.31
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.5%
Cap/Sales -3.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.63
Quick Ratio 0.63
Altman-Z -11.9
F-Score2
WACC7.89%
ROIC/WACCN/A
Cap/Depr(3y)26.93%
Cap/Depr(5y)20.36%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-47.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.09%
EPS Next Y46.17%
EPS Next 2Y18.23%
EPS Next 3Y22.28%
EPS Next 5Y13.4%
Revenue 1Y (TTM)-138.77%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%186.77%
Revenue Next Year24.15%
Revenue Next 2Y74.49%
Revenue Next 3Y23.29%
Revenue Next 5Y19.6%
EBIT growth 1Y-159.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year55.73%
EBIT Next 3Y34.05%
EBIT Next 5Y0.83%
FCF growth 1Y14.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.92%
OCF growth 3YN/A
OCF growth 5YN/A

NANOBIOTIX / NANO.PA FAQ

What is the fundamental rating for NANO stock?

ChartMill assigns a fundamental rating of 1 / 10 to NANO.PA.


What is the valuation status for NANO stock?

ChartMill assigns a valuation rating of 1 / 10 to NANOBIOTIX (NANO.PA). This can be considered as Overvalued.


What is the profitability of NANO stock?

NANOBIOTIX (NANO.PA) has a profitability rating of 0 / 10.


Can you provide the financial health for NANO stock?

The financial health rating of NANOBIOTIX (NANO.PA) is 0 / 10.